| Latest Breaking News from Modern Healthcare | Allergan, Pfizer call off proposed $160B merger | | | The biggest U.S.-based drugmaker, Pfizer, will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland -- at least on paper -- to reduce its tax bill. |
| FDA approves biosimilar of J&J's money maker Remicade | | Tuesday, April 05, 2016 6:14 PM | |
| | The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year. |
| Fairview to acquire struggling health insurer UCare | | Tuesday, April 05, 2016 5:45 PM | |
| | Fairview Health Services in Minneapolis is jumping into the health insurance business with both feet with plans to acquire UCare. The deal announced Tuesday would shake up Minnesota's healthcare business and political landscapes. |
| New inversion rules will kill Pfizer-Allergan deal | | Tuesday, April 05, 2016 5:32 PM | |
| | Drugmakers Pfizer and Allergan are scrambling to determine whether to proceed with their plan to merge and move Pfizer's address -- but not its operations or headquarters -- to lower-tax Ireland. |
| Big changes to ACO cost targets draw praise from providers | | Tuesday, April 05, 2016 1:25 PM | |
| | Major healthcare systems are generally praising the CMS' attempts to make Medicare's biggest accountable-care program more attractive as the agency strives to grow the number of participants while also persuading more of them to assume greater... |
| Hospitals get rewards for saving money. Why not patients? | | Tuesday, April 05, 2016 12:42 PM | |
| | The term "shared savings" usually brings to mind the CMS' accountable care programs and the shared rewards for hospitals that save money over the benchmark costs of care, but a select number of technology companies are taking the concept... |
| Innovation a factor in insulin drug prices tripling over past decade | | Tuesday, April 05, 2016 12:34 PM | |
| | The price of insulin, a drug that's been around for nearly a century, has been steadily rising, surpassing the cost of similar treatments and becoming an increasingly unaffordable necessity for the roughly 6 million Americans with diabetes. And in... |
|
